PRODUCT MONOGRAPH

^{Pr}ALLOPURINOL

allopurinol tablets, USP

300 mg

Xanthine oxidase inhibitor

APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 DATE OF REVISION: January 17, 2017

Submission Control No: 198729

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS	3
WARNINGS AND PRECAUTIONS	4
ADVERSE REACTIONS	5
DRUG INTERACTIONS	7
DOSAGE AND ADMINISTRATION	9
OVERDOSAGE	11
ACTION AND CLINICAL PHARMACOLOGY	11
STORAGE AND STABILITY	12
DOSAGE FORMS, COMPOSITION AND PACKAGING	12
PART II: SCIENTIFIC INFORMATION	14
PHARMACEUTICAL INFORMATION	14
CLINICAL TRIALS	15
TOXICOLOGY	15
REFERENCES	17
PART III: CONSUMER INFORMATION	19

PrALLOPURINOL

allopurinol tablets, USP

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of	Dosage Form /	Clinically Relevant Nonmedicinal
Administration	Strength	Ingredients
Oral	Tablets / 300 mg	starch, lactose, magnesium stearate, povidone. In addition the 300 mg tablets also contain FD&C Yellow#6 Lake.

INDICATIONS AND CLINICAL USE

ALLOPURINOL tablets are indicated for:

- treatment of gout, either primary, or secondary to hyperuricemia which occurs in blood dyscrasias and their therapy.
- treatment of primary or secondary uric acid nephropathy, with or without accompanying signs or symptoms of gout.
- prophylactically, to prevent tissue urate deposition or renal calculi in patients with leukemias, lymphomas or other malignancies, receiving antineoplastic treatment (radiation or cytotoxic drugs) which might induce increased uricemia levels. Also, in the therapy and prophylaxis of acute urate nephropathy and resultant renal failure in patients with neoplastic disease who are particularly susceptible to hyperuricemia and uric acid stone formation (especially after radiation therapy or use of antineoplastic drugs).
- prevention of the occurrence and recurrence of uric acid stones or gravel and renal calcium lithiasis in patients with hyperuricemia and/or hyperuricosuria.

Geriatrics (> 65 years of age):

The kinetics of ALLOPURINOL are not likely to be altered other than due to deterioration in renal function (See WARNINGS AND PRECAUTIONS Renal Function; DOSAGE AND ADMINISTRATION).

Pediatrics (6 - 10 years of age):

See CONTRAINDICATIONS

CONTRAINDICATIONS

• Patients who are hypersensitive to allopurinol or who have previously developed a severe reaction to this drug or to any ingredient in the formulation. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

• Nursing women and children (except in those with hyperuricemia secondary to malignancy).

WARNINGS AND PRECAUTIONS

<u>General</u>

Adequate therapy with ALLOPURINOL will lead to dissolution of large uric acid renal pelvic stones, with the remote possibility of impaction in the ureter.

Asymptomatic hyperuricemia *per se* is generally not considered an indication for use of ALLOPURINOL. Fluid and dietary modification with management of the underlying cause may correct the condition.

ALLOPURINOL treatment should not be started until an acute attack of gout has completely subsided, as further attacks may be precipitated.

Acute gouty attacks may be precipitated at the start of treatment with ALLOPURINOL in new patients, and these may continue even after serum uric acid levels begin to fall. Prophylactic administration of colchicine is advisable, particularly in new patients and in those where the previous attack rate has been high. In addition, it is recommended that the patient start with a low dose of ALLOPURINOL (100 mg and 200 mg daily) and the dose be built up slowly until a serum uric acid level of 6 mg/100 mL or less is attained (see DOSAGE AND ADMINISTRATION). If acute gouty attacks develop in patients receiving allopurinol, treatment should continue at the same dosage while the acute attack is treated with a suitable anti inflammatory agent.

In conditions where the rate of urate formation is greatly increased (e.g., malignant disease and its treatment; Lesch Nyhan syndrome), the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. This risk may be minimized by adequate hydration to achieve optimal urine dilution.

The incidence of adverse reactions in association with ALLOPURINOL is higher in the presence of renal and/or hepatic disorder.

<u>Hepatic</u>

Reduced doses should be administered to patients with hepatic impairment. The drug should be withdrawn if increased abnormalities in hepatic functions appear.

<u>Neurologic</u>

Due to occasional occurrence of drowsiness, patients should be alerted to the need for precautions when engaging in activities where alertness is mandatory.

Since adverse reactions such as somnolence, vertigo and ataxia have been reported in patients receiving allopurinol, patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that allopurinol does not adversely affect performance.

Renal

Reduced doses should be administered to patients with renal impairment. The drug should be withdrawn if increased abnormalities in renal functions appear. Patients under treatment for hypertension or cardiac insufficiency, for example with diuretics or ACE inhibitors, may have some concomitant impairment of renal function and allopurinol should be used with care in this group.

Skin and Hypersensitivity Reactions

ALLOPURINOL (allopurinol) should be discontinued **immediately** at the appearance of a skin rash, as the rash may be, in some instances, followed by a more severe hypersensitivity reaction, including Stevens-Johnson Syndrome, DRESS, and Toxic Epidermal Necrolysis (See ADVERSE REACTIONS).

After recovery from mild reactions, ALLOPURINOL may, if desired, be cautiously reintroduced at a small dose (e.g., 50 mg/day) and gradually increased. If the rash recurs, ALLOPURINOL should be **immediately and permanently** withdrawn as more severe hypersensitivity reactions may occur.

Special Populations

Pregnant Women: ALLOPURINOL is not recommended for use during pregnancy or in women of childbearing potential unless in the judgement of the physician, the potential benefits outweigh the possible risk to the fetus.

Nursing Women: See CONTRAINDICATIONS

Pediatrics (6 - 10 years of age): ALLOPURINOL should not be given to children with the exception of those with hyperuricemia secondary to malignancy or with Lesch-Nyhan syndrome, because safety and effectiveness have not been established in other conditions.

<u>Monitoring and Laboratory Tests:</u> The dose of ALLOPURINOL should be adjusted by monitoring serum urate concentrations and urinary urate/uric acid levels at appropriate intervals (See DOSAGE & ADMINISTRATION). Periodic liver function tests should be performed in all patients on ALLOPURINOL therapy. For patients with renal impairment, if facilities are available to monitor plasma oxipurinol concentrations, the dose of ALLOPURINOL should be adjusted to maintain plasma oxipurinol levels below 100 micromol/litre (15.2 mg/litre).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Skin reactions are the most common reactions and may occur at any time during treatment. They may be pruritic, maculopapular, sometimes scaly, sometimes purpuric and rarely exfoliative.

Blood and Lymphatic System:

There have been occasional reports of reduction in the number of circulating formed elements of the blood, including agranulocytosis, thrombocytopenia and aplastic anemia,

usually in association with renal and/or hepatic disorders or in whom concomitant drugs have been administered which have a potential for causing these reactions.

Body as a Whole: General malaise, edema, angioedema

Fever has been reported to occur with and without signs/symptoms of a more generalized hypersensitivity reaction.

Cardiac disorders: Angina, bradycardia

Ear and labyrinth disorders: Vertigo

Eye disorders: Cataract, visual disorder, macular changes

Gastrointestinal Disorders: Stomatitis, changed bowel habit. Diarrhea, intermittent abdominal pain, nausea and vomiting were reported. Gastrointestinal disorders diminish if ALLOPURINOL is taken after meals. Recurrent hematemesis has been reported as an extremely rare event, as has steatorrhoea.

Hepatic Function:

Rare reports of hepatic dysfunction ranging from asymptomatic rises in liver function tests to hepatitis (including hepatic necrosis and granulomatous hepatitis) have been reported without overt incidence of more generalised hypersensitivity.

Immune System Disorders: Hypersensitivity reactions (See Skin and Hypersensitivity Reactions). Angioimmunoblastic lymphadenopathy has been described rarely following biopsy of a generalised lymphadenopathy. It appears to be reversible on withdrawal of ALLOPURINOL.

Infections and infestations: Furunculosis

Metabolism and nutrition disorders: Diabetes mellitus, hyperlipidaemia

Psychiatric disorders: Depression

Nervous system disorders: Coma, paralysis, ataxia, neuropathy, paraesthesia, somnolence, headache, taste perversion, drowsiness, peripheral neuritis

Renal and urinary disorders: Haematuria, uraemia

Reproductive system and breast disorders: Infertility, impotence, gynaecomastia

Skin and Hypersensitivity Reactions: Skin reactions associated with exfoliation, fever, chills, nausea and vomiting, lymphadenopathy, arthralgia and/or eosinophilia including Stevens-Johnson Syndrome, DRESS, and Toxic Epidermal Necrolysis occur rarely. Associated vasculitis and tissue response may be manifested in various ways including hepatitis, renal impairment and very rarely, seizures. If such reactions do occur, it may be at any time during treatment. Allopurinol should be withdrawn **immediately and permanently.** When generalized hypersensitivity reactions have occurred, renal and/or hepatic disorders have usually been present particularly when the outcome has been fatal.

The HLA-B*5801 allele has been identified as a genetic risk factor for allopurinol associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. However, the use of genotyping as a screening tool to make decisions about treatment with allopurinol has not been established.

Angioedema has been reported to occur with and without signs and symptoms of a more generalised allopurinol hypersensitivity reaction.

Very rarely acute anaphylactic shock, fixed drug eruptions, alopecia and discoloured hair have been reported.

Vascular disorders: Hypertension

DRUG INTERACTIONS

Drug-Drug Interactions

Table 1Established or Potential Drug-Drug Interactions

Name	Effect	Clinical comment
Ampicilin/Amoxicillin	An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.	The cause of the reported association has not been established. However, it is recommended that in patients receiving allopurinol, an alternative to ampicillin or amoxicillin be used if available.
Chlorpropamide	In the presence of allopurinol, there may be competition in the renal tubule for the excretion of chlorpropamide.	When renal function is poor, the recognized risk of prolonged hypoglycemic activity of chlorpropamide may be increased if ALLOPURINOL is given concomitantly.
Coumarin Anticoagulants	It has been reported that under experimental conditions allopurinol prolongs the half-life of the anticoagulant, dicumarol.	There have been rare reports of increased effect of warfarin and other coumarin anticoagulants when co-administered with allopurinol, therefore, all patients receiving anticoagulants must be carefully monitored.
Cyclophosphamide, Doxorubicin, Bleomycin, Procarbazine and Mechloroethamine	Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, (other than leukemia), in the presence of allopurinol.	However, in a well-controlled study of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechloroethamine (mustine hydrochloride) allopurinol did not appear to increase the toxic reaction of these cytotoxic agents.
Cyclosporin	Reports suggest that the plasma concentration of cyclosporin may be increased during concomitant treatment with allopurinol.	The possibility of enhanced cyclosporin toxicity should be considered if the drugs are co-administered.

Name	Effect	Clinical comment
Didanosine	In healthy volunteers and HIV patients receiving didanosine, plasma didanosine Cmax and AUC values were approximately doubled with concomitant allopurinol treatment (300 mg daily) without affecting terminal half life.	Therefore, dose reductions of didanosine may be required when used concomitantly with allopurinol.
Mercaptopurine or Azathioprine	-	In patients receiving mercaptopurine (PURINETHOL [®]) or azathioprine (IMURAN [®]), the concomitant administration of 300 to 600 mg of ALLOPURINOL per day will require a reduction in dose to approximately one- third or one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and any toxic effects.
Phenytonin	Allopurinol may inhibit hepatic oxidation of phenytoin.	The clinical significance has not been demonstrated.
Theophylline	Inhibition of the metabolism of theophylline has been reported.	The mechanism of the interaction may be explained by xanthine oxidase being involved in the biotransformation of theophylline in man. Theophylline levels should be monitored in patient starting or increasing allopurinol therapy.
Uricosurics and Salicylates	The renal clearance of oxypurinol, the major therapeutically active metabolite of allopurinol, is increased by uricosuric agents such as probenecid or large doses of salicylate and, as a consequence, the addition of a uricosuric agent may reduce the inhibition of xanthine oxidase by oxypurinol.	However, such combined therapy may be useful in achieving minimum serum uric acid levels provided that total urinary uric acid load does not exceed the competence of the patient's renal function.
Vidarabine	Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol.	When the two products are used concomitantly extra vigilance is necessary to recognize enhanced toxic effects.

Drug-Food Interactions Interactions with food have not been established.

Drug-Herb Interactions Interactions with herbal products have not been established.

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

<u>Recommended Dose and Dosage Adjustment</u> Adults

General Considerations

ALLOPURINOL is administered orally. The total daily requirement should be divided into 1 to 3 doses. Daily doses up to and including 300 mg ALLOPURINOL may be taken once a day after a meal. Larger doses should be administered as divided doses of not more than 300 mg. It should be noted that ALLOPURINOL is generally better tolerated if taken following meals.

Treatment of Gout

The dose of ALLOPURINOL varies with the severity of the disease. The minimum effective dose is 100 mg to 200 mg. The average is 200 mg to 300 mg per day for patients with mild gout, 400 mg to 600 mg per day for patients with moderately severe tophaceous gout, and 700 mg to 800 mg in severe conditions. The maximal recommended dose is 800 mg per day in patients with normal renal function.

As no simple method of measuring the blood concentrations of ALLOPURINOL is available, the correct size and frequency of dosage for maintaining the serum uric acid just within the normal range is best determined by using the serum uric acid level as an index.

Once the daily dose of allopurinol necessary to produce the desired serum uric acid level has been determined, this dose should be continued until the serum uric acid level indicates a need for dosage adjustment.

Normal serum urate levels are achieved in one to three weeks. The upper limit of normal is about 6 mg percent for men and postmenopausal women and 5 mg percent for premenopausal women. By the selection of the appropriate dose, together with the use of uricosuric agents in certain patients, it is possible to reduce the serum uric level to normal and, if desired, to hold it as low as 2 to 3 mg percent. Combined therapy of ALLOPURINOL and uricosurics will often result in a reduction in dosage of both agents.

To reduce the possibility of an increase in acute attacks of gout during the early stages of allopurinol administration, it is recommended that the patient start with a low dose of allopurinol (100 mg to 200 mg daily) and increase at weekly intervals by 100 mg until a serum uric acid level of about 6 mg percent or less is attained. Also, a maintenance dose of colchicine should be given prophylactically when allopurinol is begun, and a high fluid intake is advisable.

In patients who are being treated with uricosuric agents, colchicine and/or antiinflammatory agents, it is wise to continue this therapy while adjusting the dosage of ALLOPURINOL until a normal serum uric acid level and freedom from acute attacks have been maintained for several months. If desired, the patient may then be transferred

to ALLOPURINOL therapy exclusively.

For the Prevention of Uric Acid Nephropathy During the Vigorous Therapy of Neoplastic Disease

Treatment with 600 mg to 800 mg daily for two or three days prior to chemotherapy of X-irradiation is advisable. Treatment should be continued at a dosage adjusted to the serum uric acid level until there is no longer a threat of hyperuricemia and hyperuricosuria.

ALLOPURINOL treatment can be maintained during the antimitotic therapy for prophylaxis of the hyperuricemia which may arise during the natural crises of the disease. In prolonged treatment, 300 mg to 400 mg of ALLOPURINOL daily is usually enough to control the serum uric acid level.

It is essential that a daily urinary output of 2 litres or more be maintained during ALLOPURINOL therapy, and neutral or alkaline urine is desirable.

Prophylaxis of Renal Calcium Lithiasis

The recommended starting dose of ALLOPURINOL for the prevention of recurrent calcium stones is 200 mg to 300 mg daily as one dose or individual doses. Therapy should be continued indefinitely. Some patients have received maintenance dosages of 200 mg to 300 mg daily for more than 7 years. In some patients, the maintenance dosage may be reduced to 100 mg to 200 mg daily.

Children (6 to 10 years of age)

For the treatment of secondary hyperuricemia associated with malignancies and in the Lesch-Nyhan syndrome, ALLOPURINOL should be given in doses of 10 mg/kg/day. The response should be evaluated after approximately 48 hours by monitoring serum uric acid and/or urinary uric acid levels and adjusting the dose if necessary.

Geriatric (> 65 years of age)

In the absence of specific data, the lowest dosage of ALLOPURINOL which produces satisfactory urate reduction should be used.

Renal Impairment

Since allopurinol and its metabolites are excreted only by the kidney, accumulation of the drug can occur in renal failure and the dose of allopurinol should consequently be reduced. With a creatinine clearance of 20 to 10 mL/min., a daily dosage of 200 mg of ALLOPURINOL is suitable. When the creatinine clearance is less than 10 mL/min., the daily dosage should not exceed 100 mg. With extreme renal impairment (creatinine clearance less than 3 mL/min.), the interval between doses may also need to be lengthened.

Hepatic Impairment

Reduced doses should be used in patients with hepatic impairment. Periodic liver function tests are recommended during the early stages of therapy.

Missed Dose

If a dose of ALLOPURINOL is missed, the patient should be advised to take it as soon as he/she remembers, and then continue with the next dose at the proper time interval.

OVERDOSAGE

Ingestion of up to 22.5 g ALLOPURINOL (allopurinol) without adverse effect has been reported. Symptoms and signs including nausea, vomiting, diarrhea, and dizziness have been reported in a patient who ingested 20 g allopurinol. Recovery followed general supportive measures.

Massive absorption of ALLOPURINOL may lead to considerable inhibition of xanthine oxidase activity, which should have no untoward effects unless affecting concomitant medication, especially with mercaptopurine and/or azathioprine. No treatment is normally required provided the drug is withdrawn and adequate hydration is maintained to facilitate excretion of the drug. If considered necessary hemodialysis may be used. Otherwise the treatment is symptomatic.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

ALLOPURINOL is a structural analogue of hypoxanthine. Reduction in both the serum and urinary uric acid levels is brought about by allopurinol inhibiting the action of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol, which is also an inhibitor of xanthine oxidase. The action of allopurinol in blocking formation of urate differs from that of uricosuric agents which lower the serum uric acid level by increasing urinary excretion of uric acid.

When taken orally, allopurinol is rapidly absorbed and rapidly metabolized. The main metabolite is oxypurinol, which is itself a xanthine oxidase inhibitor. Allopurinol and its metabolites are excreted by the kidney. The renal handling is such that allopurinol has a plasma half-life of about one hour, whereas that of oxypurinol exceeds 18 hours. Thus, the therapeutic effect can be achieved by a once a day dosage of ALLOPURINOL in patients taking 300 mg or less per day.

Administration of allopurinol generally results in a fall in both serum and urinary uric acid within 2-3 days. The magnitude of the decrease can be adjusted to a certain extent by varying the dose of allopurinol. The serum uric acid levels fall gradually and therefore a week or more of allopurinol treatment may be necessary before the full effect is obtained. Uric acid returns to pre-treatment levels slowly, usually after a cessation of therapy. This is due primarily to the accumulation and slow clearance of oxypurinol. In some patients, particularly those with tophaceous gout, a significant fall in urinary uric acid excretion may not occur, possibly due to the mobilization of urate from tissue

deposits as the serum uric acid level begins to fall.

The combined increase in hypoxanthine and xanthine excreted in the urine is usually, but not always, considerably less than the accompanying decline in urinary uric acid. This may be due to pseudofeedback inhibition of purine biosynthesis by allopurinol ribotide.

It has been shown that reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol. This reutilization and the normal feedback inhibition which would result from an increase in available purine nucleotides serve to regulate purine biosynthesis, and, in essence, the defect of the over-producer of uric acid is thereby compensated.

Innate deficiency of xanthine oxidase, which occurs in patients with xanthinuria, as an inborn error of metabolism has been shown to be compatible with comparative wellbeing. While urinary levels of oxypurines attained with full doses of allopurinol may in exceptional cases equal those (250-600 mg/day) which in xanthinuric subjects have caused formation of urinary calculi, they usually fall in the range of 50-200 mg and no evidence of renal damage has been clinically observed. Xanthine crystalluria has been reported in a few exceptional cases. The serum concentration of oxypurines in patients receiving allopurinol is usually in the range of 0.3 mg to 0.4 mg percent, compared with a normal level of approximately 0.15 mg percent. A maximum of 0.9 mg percent was observed when the serum urate was lowered to less than 2 mg percent by high doses of the drug. In one exceptional case, a value of 2.7 mg percent was reached. These are far below the saturation level at which precipitation of xanthine or hypoxanthine would be expected to occur so that tissue deposition is unlikely and has not been observed to date. The solubilities of uric acid and xanthine in the serum are similar (about 7 mg percent) while hypoxanthine is much more soluble.

The finding that the renal clearance of oxypurines is at least ten times greater than that of uric acid explains the relatively low serum oxypurine concentration at a time when the serum uric acid level has decreased markedly. At serum oxypurine levels of 0.3 to 0.9 mg percent, oxypurine: inulin clearance ratios were between 0.7 and 1.9. The glomerular filtration rate and urate clearance in patients receiving allopurinol do not differ significantly from those obtained prior to therapy. The rapid renal clearance of oxypurines suggests that allopurinol therapy should be of value in allowing a patient with gout to increase his total purine excretion.

STORAGE AND STABILITY

ALLOPURINOL should be stored between 15 and 30°C.

DOSAGE FORMS, COMPOSITION AND PACKAGING

ALLOPURINOL 300 mg tablets are available in bottles of 100. Each peach-coloured, round, biconvex tablet contains 300 mg allopurinol and is scored on one side.

Each ALLOPURINOL 300 mg tablet contains the following nonmedicinal ingredients:

corn starch, lactose, magnesium stearate and povidone. In addition, the 300 mg tablet also contains FD&C yellow #6 Lake.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: allopurinol

Chemical name: 1,5-dihydro-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-one

Molecular formula and molecular mass: $C_5H_4N_4O_1$, 136.11

Structural formula:



Physicochemical properties:

Description: Allopurinol is a position isomer of the natural purine base hypoxanthine. It is a colourless, odourless, tasteless, solid, insoluble in cold water and dissolves in about 250 parts of hot water. It can be dissolved in water by the addition of one molecular equivalent of sodium hydroxide.

CLINICAL TRIALS

Data not available.

TOXICOLOGY

<u>Animals</u>

In mice, the LD_{50} is 700 mg/kg p.o. In rats, the acute LD_{50} is greater than 6 g/kg p.o.

In a 13-week feeding experiment in rats, 2 of 10 rats treated at a drug level of 72 mg/kg/day, and 4 of 10 rats treated with 225 mg/kg/day, died before the completion of the experiment. Both groups exhibited renal tubular damage due to the deposition of xanthine that was more extensive at the higher dose. In chronic feeding experiments, rats showed no toxic effects at a level of 14 mg/kg/day after one year. At a level of 24 mg/kg/day for one year, the rats showed very slight depression of weight gain and food intake, and five out of ten of the animals showed minor changes in the kidney tubules of the type exhibited by the rats on the higher doses described above. Dogs survived oral dosing at 30 mg/kg/day for one year with nil to minor changes in the kidney and no other significant abnormalities. At 90 mg/kg/day for one year, there was some accumulation of xanthine in the kidneys with resultant chronic irritation and slight tubular changes. Occasional hemosiderin-like deposits were seen in the reticuloendothelial system. A higher dose (270 mg/kg/day) resulted in large concretions in the renal pelves, with severe destructive changes in the kidney secondary to xanthine accumulation. The deposit of xanthine appears to be a f unction of both the metabolic turnover of purines (which is proportionately larger in the smaller animals) and the degree of inhibition of xanthine oxidase.

Reproductive studies in rats and rabbits indicated that allopurinol did not affect litter size, the mean weight of the progeny at birth or at three weeks postpartum, nor did it cause an increase in the number of animals born dead or with malformations.

Cytogenetic studies show that allopurinol does not induce chromosome aberrations in human blood cells *in vitro* at concentrations up to $100 \ \mu\text{g/mL}$ and *in vivo* at doses up to $600 \ \text{mg/day}$ for a mean period of 40 months.

Allopurinol does not produce nitroso compounds *in vitro* or affect lymphocyte transformation *in vitro*.

Evidence from biochemical and other cytological investigations strongly suggests that allopurinol had no deleterious effects on DNA at any stage of the cell cycle and is not mutagenic.

No evidence of carcinogenicity has been found in mice and rats treated with allopurinol for up to 2 years.

One study in mice receiving intraperitoneal doses of 50 or 100 mg/kg on days 10 or 13 of gestation resulted in fetal abnormalities, however in a similar study in rats at 120 mg/kg on day 12 of gestation no abnormalities were observed. Extensive studies of high oral doses of allopurinol in mice up to 150 mg/kg/day during days 8 to 16 of gestation

produced no teratogenic effects.

An *in vitro* study using fetal mouse salivary glands in culture to detect embryotoxicity indicated that allopurinol would not be expected to cause embryotoxicity without also causing maternal toxicity.

REFERENCES

- 1. Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 15(7):863-880, 1966.
- 2. Elion GB, Yu TF, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Amer. J. Med. 45(1):69-77, 1968.
- 3. Krakoff, IH. Clinical pharmacology of drugs which influence uric acid production and excretion Clin. Pharmac. Ther. 8(1):124-138, 1967.
- 4. Muggia F, Ball TJ Jr., Ultmann JE. Allopurinol in the Treatment of Neoplastic Disease Complicated by Hyperuricemia, Archs. Intern. Med. 120(1):12-18, 1967.
- 5. Rundles RW, Metz EN, Silberman HR. Allopurinol in the Treatment of Gout; Ann. Intern. Med. 64(2):229-258, 1966.
- 6. Rundles RW, Wyngaarden JB, Hitchings GH. Effects of a Xanthine Oxidase Inhibitor on Thiopurine Metabolism, Hyperuricemia and Gout. Trans. Ass. Am. Phycns. 76:126-140, 1963.
- 7. Seegmiller JE, Grayzel AI. Use of the Newer Uricosuric Agents in the Management of Gout. J. Am. Med. Ass. 173:1076-1080, 1960.
- 8. Woodbury JF, Mehta DM, Morse WI. Allopurinol in the Treatment of Gout; Nova Scotia Med. Bull., 48:103-107 (August) 1969.
- 9. Yue TF, Gutman AB. Effect of Allopurinol (4- hydroxypyrazolo-(3,4-D) pyrimidine) on Serum and Urinary Uric Acid in Primary and Secondary Gout. Am. J. Med. 37:885-898, 1964.
- 10. Smith MJ. Placebo versus Allopurinol for Renal Calculi; J. Urol. 117(6):690-692, 1977.
- 11. Coe FL. Treated and Untreated Recurrent Calcium Nephrolithiasis in Patients with Idiopathic Hypercalciuria, Hyperuricosuria, or No Metabolic Disorder; Ann. Intern. Med. 87(4):404-410, 1977.
- 12. Coe FL, Raisen L. Allopurinol Treatment of Uric-Acid Disorders in the Calcium-Stone Formers. Lancet. 1(7795):129-131, 1973.
- 13. Coe FL, Kavalach AG. Hypercalciuria and Hyperuricosuria in Patients with Calcium Nephrolithiasis; New Engl. J. Med. 291(25):1344-1350, 1974.
- Vabusek M. Prevention of Urinary Calculi in Hyperuricemia and Gout. Urolithiasis Research, Ed. Fleisch et al., Plenum Press, New York, pp. 565-568, 1976.

- 15. Friedman HM, Grasela T. Adenine arabinoside and allopurinol possible adverse drug interaction. New Engl. J. Med. 304: 423, 1981.
- Yokochi K, Yokochi A, Chiba K, et al. Phenytoin--allopurinol interaction: Michaelis-Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch-Nyhan syndrome. Therap. Drug Monitoring. 4(4): 353-357, 1982.
- 17. Manfredi RL, Vesell ES. Inhibition of theophylline metabolism by long term allopurinol administration. Clin. Pharmac. Ther. 29(2): 224-229, 1981.
- 18. Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricaemia. J. Clin. Pharm. 21: 456 468, 1981.
- 19. Boston Collaborative Drug Surveillance Program. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. J. Am. Med. Ass. 227: 1036-1040, 1974.
- 20. Stolbach L, Begg C, Bennett JM, Silverstein M, Falkson G, Harris DT, et al. Evaluation of bone marrow toxic reaction in patients treated with allopurinol. J. Am. Med. Ass. 247(3): 334-336, 1982.
- 21. Stevens SL, Goldman MH. Cyclosporin toxicity associated with allopurinol. South. Med. J. 85(12): 1265-1266, 1992.
- 22. Gorrie M, Beaman M, Nicholls A, Backwell P. Allopurinol interaction with cyclosporin. Brit. Med. J. 308:113, 1994.

PART III: CONSUMER INFORMATION

PrALLOPURINOL allopurinol

This leaflet is part III of a three-part "Product Monograph" published for ALLOPURINOL, approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about ALLOPURINOL. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for: ALLOPURINOL is used for:

- treatment of gout (a painful inflammation primarily of the big toe),
- treatment of kidney problems due to high uric acid levels
- treatment or prevention of uric acid deposits in the tissues or kidneys due to high levels of uric acid in the blood, which may also be caused by certain cancer treatments.
- prevention of uric acid stones or gravel and kidney stone in patients with high levels of uric acid in blood or urine.

What it does:

ALLOPURINOL works by reducing the production of uric acid in the body.

When it should not be used:

ALLOPURINOL should not be used:

- if you are allergic to the active ingredient allopurinol or had a previous serious allergic reaction to allopurinol or any ingredient in ALLOPURINOL (See what the medicinal ingredient is and what the nonmedicinal ingredients are sections).
- if you are breastfeeding.
- if you are less than 18 years old except in children with hyperuricemia (a high level of uric acid in the blood) secondary to cancerous growths.

What the medicinal ingredient is:

The medicinal ingredient in ALLOPURINOL is allopurinol.

What the important nonmedicinal ingredients are:

ALLOPURINOL contains the following nonmedicinal ingredients: starch, lactose, magnesium stearate, povidone. In addition, the 300 mg tablets contain FD&C Yellow #6 Lake.

What dosage forms it comes in:

ALLOPURINOL is available as 300 mg tablets.

WARNINGS AND PRECAUTIONS

BEFORE you **use ALLOPURINOL** talk to your doctor or pharmacist:

- if you are allergic to allopurinol or any other medications.
- about all your medical conditions, including a history of kidney or liver disease or heart disease.
- if you are pregnant or plan to become pregnant.

Gout attacks may occur at the start of treatment.

If you get a skin rash, discontinue use **immediately** and contact your doctor (See serious side effects, how often they happen, and what to do about them).

Do not drive or operate machinery if feeling sleepy or drowsy.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor what prescription and non-prescription medications, vitamins, nutritional supplements and herbal products you are taking, especially: chemotherapy agents coumarin, anticoagulants amoxicillin/ampicillin chlorpropamide didanosine phenytoin theophylline salicylates and uricosurics probenecid cyclosporine vidarabine

PROPER USE OF THIS MEDICATION

Usual dose:

Adults

General:

The total daily requirement should be divided into 1 to 3 doses. Daily doses up to and including 300 mg ALLOPURINOL may be taken once a day after a meal. You should drink plenty of fluids while taking ALLOPURINOL.

Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ALLOPURINOL exactly as directed. Do not take more or less than prescribed by your doctor.

Overdose:

Symptoms and signs of overdosage include nausea, vomiting, diarrhea and dizziness.

For management of a suspected drug overdose, contact

your regional Poison Control Centre.

Missed Dose:

If you forget to take your medicine, take it as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

ALLOPURINOL can cause some **side effects**. Tell your doctor if any of these symptoms are severe or do not go away:

 dizziness, drowsiness, diarrhea, abdominal pain, nausea, vomiting, headache, visual disturbances.

Seek emergency medical attention or contact your doctor immediately if you experience any of the following:

- an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
- painful urination, blood in the urine;
- yellow skin or eyes.

Gout attacks may occur at the start of treatment.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Frequency	Side effect/ Symptom	Talk with your doctor or pharmacist		Stop taking drug and call your doctor or
		Onl y if seve re	In all cas es	pharmacist
Common	Skin rash and hypersensitivit y reactions (serious allergic reactions)			\checkmark
Uncommon	Drowsiness, diarrhea, abdominal pain, nausea, vomiting.			\checkmark

This is not a complete list of side effects. For any unexpected effects while taking ALLOPURINOL,

contact your doctor or pharmacist.

HOW TO STORE IT

ALLOPURINOL should be stored between 15 and 30°C, out of the reach of children.

REPORTING SUSPECTED SIDE EFFECTS You can **report any suspected adverse reactions associated with** the use of health products **to the Canada Vigilance Program** by **one of the following 3 ways:**

 Report online at <u>www.healthcanada.gc.ca/medeffect</u>
 Call toll-free at 1-866-234-2345
 Complete a Canada Vigilance Reporting Form and: Fax toll-free to 1-866-678-6789, or

 Mail to: Canada Vigilance Program
 Health Canada
 Postal Locator 0701C
 Ottawa, ON
 K1A 0K9
 Postage paid labels, Canada Vigilance
 Reporting Form and the adverse reaction
 reporting guidelines are available on the

MedEffect[™] Canada Web site at

www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

- For more information, please contact your doctor, pharmacist or other healthcare professional.
- This leaflet plus the full product monograph, prepared for health professionals, can be obtained by contacting DISpedia, Apotex's Drug Information Service, at 1-800-667-4708.

This leaflet can also be found at <u>http://www.apotex.ca/products</u>

This leaflet was prepared by Apotex Inc., Toronto, Ontario, M9L 1T9.

Last revised: January 17, 2017